Sequential prescription of antifungals in invasive fungal infection: the importance of mechanism of action

International Journal of Antimicrobial Agents

Volumn 32, Issue SUPPL. 2, 2008, Pages

  Candel, F J ^a   Matesanz, M ^a   Mensa, J ^b  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Antifungal antagonism; Antifungal combinations; Calcineurin inhibitors; Iron chelators

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CALCINEURIN INHIBITOR; CASPOFUNGIN; CICLOPIROXOLAMINE; COTRIMOXAZOLE; CYCLOSPORIN A; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; POSACONAZOLE; RAPAMYCIN; TACROLIMUS; TERBINAFINE; TRIAZOLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; CANDIDEMIA; COMBINATION CHEMOTHERAPY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYDROPHOBICITY; IRON CHELATION; MONOTHERAPY; MUCORMYCOSIS; MYCOSIS; NEUTROPENIA; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CHELATING AGENTS; DRUG ANTAGONISM; DRUG SYNERGISM; FUNGI; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYCOSES; SALVAGE THERAPY;

EID: 55649120644     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(08)70014-1     Document Type: Article

References (21)

1. Patterson T.F., Boucher H.W., Herbrecht R., et al. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis 41 (2005) 1448-1452
2. Maertens J., Raad I., Petrikkos G., et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39 (2004) 1563-1571
3. Denning D.W., Marr K.A., Lau W.M., et al. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 53 (2006) 337-349
4. Baden L.R., Katz J.T., Fishman J.A., et al. Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy. Transplantation 76 (2003) 1632-1637
5. Walsh T.J., Raad I., Patterson T.F., et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 44 (2007) 2-12
6. Xiao L., Madison V., Chau A.S., Loebenberg D., Palermo R.E., and McNicholas P.M. Three-dimensional models of wild-type and mutated forms of cytochrome P450 14a-sterol demethylases from Aspergillus fumigatus and Candida albicans provide insights into posaconazole binding. Antimicrob Agents Chemother 48 (2004) 568-574
7. Louie A., Kaw P., Banerjee P., Liu W., Chen G., and Miller M.H. Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis. Antimicrob Agents Chemother 45 (2001) 485-494
8. Kirkpatrick W.R., Coco B.J., and Patterson T.F. Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a Guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 50 (2006) 1567-1569
9. Boogaerts M., Winston D.J., Bow E.J., et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med 135 (2001) 412-422
10. Solé A., Morant P., Salavert M., Pemán J., Morales P., and Valencia Lung Transplant Group. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 11 (2005) 359-365
11. Kontoyiannis D.P., Boktour M., Hanna H., Torres H.A., Hachem R., and Raad I.I. Itraconazole added to a lipid formulation of amphotericin B does not improve outcome of primary treatment of invasive aspergillosis. Cancer 103 (2005) 2334-2337
12. Rex J.H., Pappas P.G., Karchmer A.W., et al. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 36 (2003) 1221-1228
13. Marr K., Boeckh M., Carter R.A., Kim H.W., and Corey L. Combination antifungal therapy for invasive aspergillosis. Cin Infect Dis 39 (2004) 797-802
14. Singh N., Limaye A.P., Forrest G., et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 81 (2006) 320-326
15. Kontoyiannis D.P., Chamilos G., Lewis R.E., et al. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer 110 (2007) 1303-1306
16. Alexander J., Limaye A.P., Ko C.W., Bronner M.P., and Kowdley K.V. Association of hepatic iron overload with invasive fungal infection in liver transplant recipients. Liver Transpl 12 (2006) 1799-1804
17. Sigle H.C., Thewes S., Niewerth M., Korting H.C., Scḧafer-Korting M., and Hube B. Oxygen accessibility and iron levels are critical factors for the antifungal action of ciclopirox against Candida albicans. J Antimicrob Chemother 55 (2005) 663-673
18. Niewerth M., Kunze D., Seibold M., Schaller M., Korting H.C., and Hube B. Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors. Antimicrob Agents Chemother 47 (2003) 1805-1817
19. Ibrahim A.S., Edwards Jr. J.E., Fu Y., and Spellberg B. Deferiprone iron chelation as a novel therapy for experimental mucormycosis. J Antimicrob Chemother 58 (2006) 1070-1073
20. Ibrahim A.S., Gebermariam T., Fu Y., et al. The iron chelator deferasirox protects mice from mucormycosis through iron starvation. J Clin Invest 117 (2007) 2649-2657
21. Reed C., Ibrahim A., Edwards Jr. J.E., Walot I., and Spellberg B. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 50 (2006) 3968-3969